Epizyme (EPZM) PT Lowered to $12 at Cowen, Following Earnings

Cowen analyst Joseph Thome lowered the price target on Epizyme (NASDAQ: EPZM) to $12.00 (from $14.00) while maintaining a Outperform rating.

Analyst comments: "Q3 Tazverik revenues came in below consensus; however, a focus on expanding Tazverik's reach via changes in commercial strategy and clinical and geographical expansion could improve the outlook in the long-term. Advancement in Tazverik combination basket studies for heme and solid tumors and the Ph. I for EZM0414 is a key area of focus over the coming months."

You May Also Be Interested In

• ZoomInfo Technologies (GTM) PT Lowered to $4.25 at DA Davidson to Reflect Sector Headwinds
• Lineage Inc (LINE) PT Lowered to $48 at Goldman Sachs
• Envista Holdings Corp. (NVST) PT Lowered to $26 at BMO Capital Following China VBP Commentary